JP Morgan Maintains Overweight on Vera Therapeutics, Raises Price Target to $65
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Anupam Rama maintains an Overweight rating on Vera Therapeutics (NASDAQ:VERA) and raises the price target from $60 to $65.
May 31, 2024 | 5:20 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JP Morgan analyst Anupam Rama maintains an Overweight rating on Vera Therapeutics and raises the price target from $60 to $65.
The Overweight rating and increased price target from a reputable analyst at JP Morgan is likely to boost investor confidence in Vera Therapeutics, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100